ROGERS (ROG) Company Report

Genentech, a member of the Roche Group, announced an agreement with the U.S. government to address prescription drug costs and encourage biopharmaceutical innovation.
Under the agreement, Genentech will make many of its medicines available for state Medicaid programs at prices comparable to those in other wealthy countries and expand its direct-to-patient flu medicine program via TrumpRx.gov.
The company reaffirmed its commitment to U.S. manufacturing, infrastructure, and R&D, building on a recent $50 billion investment that is expected to create over 11,000 jobs.
As part of the agreement, Genentech received a three-year exemption from tariffs and will not be subject to future pricing mandates.

Dec 19, 2025, 7:28 PM

Press Release

ROG's Giredestrant Shows Positive Phase III Results for Breast Cancer Treatment

ROG

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Giredestrant, an experimental oral selective estrogen receptor degrader (SERD), demonstrated a 30% reduction in the risk of invasive disease recurrence or death in patients with early-stage, hormone receptor-positive, HER2-negative breast cancer, according to phase III lidERA trial results.
The trial, presented at the 2025 San Antonio Breast Cancer Symposium, showed 92.4% of patients on giredestrant were alive and disease-free after three years, compared to 89.6% on standard therapy, and the drug also reduced distant metastasis risk by 31%.
This marks the first time an oral SERD has shown a statistically significant and clinically meaningful disease-free survival benefit in the adjuvant setting, potentially establishing giredestrant as a new standard-of-care treatment.
Roche and Genentech (ROG) anticipate worldwide regulatory submissions for giredestrant, with projected revenues up to $5 billion per year if approved.

Dec 10, 2025, 1:26 PM

Morningstar

Roche Invests in Blood-Brain Barrier Therapeutics Collaboration

ROG

New Projects/Investments

Roche has committed $55 million upfront to a strategic collaboration with Manifold Bio to develop next-generation blood-brain barrier (BBB) shuttles aimed at improving the delivery of therapeutics for neurological and neurodegenerative diseases.
The partnership utilizes Manifold Bio's AI-driven mDesign platform, which performs high-throughput, direct-to-vivo screening of biologic candidates to accelerate drug discovery.
If successful, the deal could generate milestones exceeding $2 billion plus royalties for Manifold Bio.
This investment builds on Roche’s existing Brainshuttle technology, which is currently in clinical trials for diseases such as Alzheimer’s and multiple sclerosis.

Nov 3, 2025, 12:03 PM

Morningstar

Roche Announces Strategic Collaboration with Manifold Bio

ROG

New Projects/Investments

Roche has entered into a strategic research collaboration and license agreement with Manifold Bio to develop multiple next-generation brain shuttles for neurological and neurodegenerative diseases.
Manifold Bio will receive an upfront payment of $55 million from Roche.
The agreement includes potential for Manifold Bio to receive over $2 billion in total research, preclinical, clinical development, and commercial milestones, along with tiered royalties.
Manifold Bio will lead research and discovery activities, while Roche will be responsible for preclinical, clinical, and commercialization efforts.

Nov 3, 2025, 11:45 AM

Press Release

ROG Reports Q3 2025 Results and Provides Q4 2025 Guidance

ROG

Earnings

Guidance Update

Demand Weakening

ROG reported Q3 2025 net sales of $216.0 million and adjusted earnings per diluted share of $0.90, with both results at the high-end of guidance.
The company achieved an Adjusted EBITDA margin of 17.2% and generated $21 million of free cash flow in Q3 2025.
For Q4 2025, ROG anticipates net sales between $190 million and $205 million and adjusted earnings per diluted share between $0.40 and $0.80.
The Q4 outlook projects a sequential decline in sales due to normal seasonality, with an expected adjusted EBITDA margin of 15%.

Oct 29, 2025, 9:00 PM

Presentation

Rogers Corporation Reports Q3 2025 Results and Provides Q4 2025 Outlook

ROG

Earnings

Guidance Update

Share Buyback

Rogers Corporation reported Q3 2025 sales at the upper end of guidance, increasing 6.5% sequentially and 2.7% year-over-year, with adjusted EPS of $0.90.
For Q4 2025, the company projects sales between $190 million and $205 million, representing a 3% year-over-year increase at the midpoint, and anticipates adjusted EPS between $0.40 and $0.80.
Adjusted EBITDA margin improved by 540 basis points sequentially to 17.2% in Q3 2025 and is guided to improve by 300 basis points year-over-year at the midpoint in Q4 2025.
Production commenced at the new ceramic facility in China in Q3, which is anticipated to create an 80 basis point headwind to Q4 gross margin due to ramp-up costs.
The company is targeting $13 million in annualized savings from German ceramic operations restructuring by late 2026 and expects Q4 share repurchases to exceed Q3 levels, with $66 million remaining on the current program.

Oct 29, 2025, 9:00 PM

Transcript

Rogers Corporation Announces Third Quarter 2025 Results and Q4 2025 Outlook

ROG

Earnings

Guidance Update

Revenue Acceleration/Inflection

Rogers Corporation reported net sales of $216.0 million for Q3 2025, representing a 6.5% sequential increase.
GAAP diluted earnings per share for Q3 2025 were $0.48, a significant improvement from $(4.00) in the prior quarter, with adjusted earnings per diluted share reaching $0.90.
The company's gross margin for Q3 2025 was 33.5%, an increase of 190 basis points sequentially.
For Q4 2025, Rogers Corporation anticipates net sales to be between $190 million and $205 million, and adjusted earnings per diluted share to range from $0.40 to $0.80.

Oct 29, 2025, 8:08 PM

8-K

Rogers Corporation Reports Third Quarter 2025 Results

ROG

Earnings

Guidance Update

Share Buyback

Rogers Corporation reported net sales of $216.0 million for the third quarter of 2025, marking a 6.5% sequential increase.
GAAP earnings per share for Q3 2025 were $0.48, a significant improvement from $(4.00) in the prior quarter, while adjusted earnings per share rose to $0.90 from $0.34 sequentially.
The company's gross margin increased by 190 basis points sequentially to 33.5% in Q3 2025.
For the fourth quarter of 2025, Rogers Corporation anticipates net sales to be in the range of $190 million to $205 million and adjusted earnings per diluted share between $0.40 and $0.80.
In Q3 2025, net cash provided by operating activities was $28.9 million, and free cash flow was $21.2 million, with share repurchases totaling $10.0 million.

Oct 29, 2025, 8:05 PM

Press Release

Genentech Announces Phase III Vamikibart Trial Results

ROG

New Projects/Investments

Genentech, a member of the Roche Group, announced positive results from two Phase III studies (MEERKAT and SANDCAT) for its investigational drug vamikibart in uveitic macular edema (UME).
Vamikibart, a potential first-in-class non-steroid targeted therapy, demonstrated rapid improvements in vision and reductions in macular thickness. The MEERKAT study achieved statistically significant superiority over sham for the primary endpoint of vision improvement.
The drug was generally well tolerated, with a low incidence of treatment-related ocular adverse events, addressing a significant unmet need given the side effects of current steroid treatments for UME.
Genentech plans to discuss these data with health authorities globally for potential regulatory approval.

Oct 17, 2025, 8:20 PM

Press Release

Rogers Corporation Announces Board Chair Transition and Plans for New Independent Director

ROG

Board Change

Rogers Corporation announced that Peter Wallace, Chair of the Board of Directors, will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders.
Armand Lauzon, an existing Board member since 2023, has been elected as the new Chair, effective immediately.
The company plans to appoint a new independent director to the Board with input from Starboard Value LP.
Following these changes, Starboard Value confirmed it does not intend to nominate directors for election at the Company’s 2026 Annual Meeting of Shareholders.